Experimental Drug May Benefit Patients With AI-Resistant BC

cp418

Experimental Drug May Benefit Patients With AI-Resistant Breast Cancer.

MedPage Today (9/19, Bankhead) reports, "A tamoxifen-like drug slowed progression of advanced postmenopausal breast cancer previously treated with a nonsteroidal aromatase inhibitor [AI], according to" a study presented at the Breast Cancer Symposium. Researchers reported that "in a phase II trial, patients with hormone receptor-positive breast cancer treated with toremifene (Fareston) had a clinical benefit rate almost double that of women treated with the steroidal aromatase inhibitor exemestane (Aromasin)." The investigators reported that "the progression hazard was reduced by 38% in the toremifene arm, although objective response rate and overall survival did not differ between treatment groups."

http://www.medpagetoday.com/MeetingCoverage/MBCS/34840